Professor Garland is an internationally recognized clinical microbiologist and sexual health physician, with particular expertise in infectious diseases as they pertain to reproductive health and the neonate. With her team, Prof Garland, has been a leader in the role of patient self-collected genital sampling in the detection by molecular techniques (polymerase chain reaction (PCR) of reproductive tract infections, particularly those sexually transmitted (STI), such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and especially human papillomaviruses (HPV). She has published extensively on clinical epidemiology of STIs in Australia, with a focus on HPV. Her group has defined HPV in cervical dysplasia, cervical cancer, plus the healthy population within Australia. She was chief investigator of the study defining the prevalence of HPV genotypes in urban, rural, indigenous and non-indigenous Australian women (WHINURS project) pre-HPV vaccination program in Australia. She was chief investigator of two 4-year follow-up clinical trials of prophylactic HPV vaccines in young women, plus one in mid-age women. She leads an HPV vaccine effectiveness trial (VACCINE) in Australia which will be informative globally, particularly with the WHINURS data as baseline with which to compare outcomes post vaccination. She is a regular Advisor to the WHO, largely in the area of STI diagnosis, prophylactic HPV vaccines, as well as international standards for HPV DNA assays. She is invited to deliver keynote and plenary presentations at national and international meetings. Professor Garland is the Director of the Centre for Women’s Infectious Diseases (WCID) at the Royal Women’s Hospital, the first clinical group to be centred in Bio 21 Institute, with affiliations to University of Melbourne Faculty of Medicine Dentistry and Health Sciences and the Department of Obstetrics and Gynaecology. WCID conducts clinical research, cutting edge molecular diagnostics as well as STI genosurveillance. Whilst key research areas of focus include cervical cancer, sexual health and mother-to-baby infections, it has an emphasis on providing evidence for changes that may translate into clinical practice, affecting patient health.